BCL2 and ovarian carcinoma: XIAP can directly bind to and inhibit both the initiator and effector caspases and inhibit both mitochondria-dependent and mitochondrial-independent apoptotic pathways.41, 42 Treatment of ovarian cancer cells with cisplatin downregulated Bcl-2 and XIAP.